Table 1.
Overview of cell-based clinical trials for the treatment of COVID-19.
| Strategy | Type | Study Title | Phase | NCT number |
|---|---|---|---|---|
| Treg | – | Regulatory T Cell infusion for Lung Injury Due to COVID-19 pneumonia | 1 | NCT04468971 |
| RAPA-501-Allo Therapy of COVID-19-ARDS | 1 & 2 | NCT04482699 | ||
| NK | NK | Clinical Trial on NK Cells for COVID-19 | 1 | NCT04634370 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 | 1 & 2 | NCT04365101 | ||
| CAR-NK | Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 | 1 & 2 | NCT04324996 | |
| MSC | Ad-MSCs | Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 | 2 | NCT04428801 |
| BM-MSCs | Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV) | NCT04361942 | ||
| mesenchymal Stem Cell Infusion for COVID-19 Infection | 1 | NCT04444271 | ||
| Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia | 1 | NCT04713878 | ||
| mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | 1 | NCT04345601 | ||
| Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation | 1 | NCT04397796 | ||
| UC-MSCs | Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19 | 1 | NCT04366271 | |
| Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia | 1 & 2 | NCT04339660 | ||
| Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19 | Early Phase 1 | NCT04456361 | ||
| Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19) | 2 | NCT04288102 | ||
| Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS) | 1 & 2 | NCT04355728 | ||
| Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS | 1 & 2 | NCT04333368 | ||
| Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome | 1 & 2 | NCT04400032 | ||
| Mesenchymal Stem Cells for the Treatment of COVID-19 | 1 | NCT04573270 | ||
| NHPBSC | study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19 | 1 & 2 | NCT04473170 | |
| DP-MSCs | Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells | 1 | NCT04302519 | |
| Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients | 1 & 2 | NCT04336254 | ||
| SBI-101 | A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy | 1 & 2 | NCT04445220 | |
| HCT-MSCs | hCT-MSCs for COVID19 ARDS | 1 & 2 | NCT04399889 | |
| HB-adMSCs | A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 | 2 | NCT04349631 | |
| A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 | 2 | NCT04348435 | ||
| MD-MSCs | Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells | 1 & 2 | NCT04382547 | |
| Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients | 1 | NCT04535856 | ||
| Not determined | Clinical Use of Stem Cells for the Treatment of Covid-19 | 1 & 2 | NCT04392778 | |
| Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome | 1 | NCT04447833 | ||
| Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 | Early Phase 1 | NCT04371601 | ||
| DC | – | Dendritic Cell Vaccine to Prevent COVID-19 | 1 & 2 | NCT04685603 |
| Specific T cell | – | Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19 | 1 | NCT04351659 |
| Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19 | 1 &2 | NCT04457726 | ||
| SARS-CoV-2 Specific Cytotoxic T Lymphocytes for the Treatment of COVID-19 in Patients With Cancer | 1 | NCT04742595 | ||
| memory T and B cell | – | COVID-19: SARS-CoV-2 Specific Memory B and T-CD4± Cells | NCT04402892 | |
| Safety Infusion of Natural Killer cells or Memory T Cells as Adoptive Therapy in COVID-19 pneumonia or Lymphopenia | 1 &2 | NCT04578210 | ||
| monocyte | – | The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19 | 1 &2 | NCT04805086 |
Dental pulp: DP
Non-hematopoietic peripheral blood stem cells: NHPBSC
Mucosa-derived Mesenchymal Stem Cells: MD-MSCs
Allogeneic hybrid Treg/Th2 cell (RAPA-501-ALLO)
Human cord tissue mesenchymal stromal cells: HC-MSCs
Hope biosciences autologous mesenchymal stem cell: HB-adMSCs